Type 1 diabetes mellitus with other diabetic kidney complication
Methodology & AI Transparency ⓘ
Type 1 diabetes mellitus with other diabetic kidney complication Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Type 1 & Type 2 Diabetes practice, Type 1 diabetes mellitus with other diabetic kidney complication (ICD-10 E10.29) is stratified through hemoglobin A1c tracking [Type 1 diabetes mellitus with other diabetic kidney complication E10.29], pairing targeted symptom control with longitudinal Fasting Plasma Glucose [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code E10.29 categorizes Type 1 diabetes mellitus with other diabetic kidney complication under Type 1 & Type 2 Diabetes.
- 3 Typical cash cost range: Primary evaluation for Type 1 diabetes mellitus with other diabetic kidney complication incorporates hemoglobin A1c tracking [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Type 1 diabetes mellitus with other diabetic kidney complication: maintaining Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] within 4.8% – 5.6% (< 6.5% clinical target) (E10.29).
Ask our AI Specialists anything about Type 1 diabetes mellitus with other diabetic kidney complication
What Is Type 1 diabetes mellitus with other diabetic kidney complication?
Within Type 1 & Type 2 Diabetes practice, Type 1 diabetes mellitus with other diabetic kidney complication (ICD-10 E10.29) is stratified through hemoglobin A1c tracking [Type 1 diabetes mellitus with other diabetic kidney complication E10.29], pairing targeted symptom control with longitudinal Fasting Plasma Glucose [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Type 1 diabetes mellitus with other diabetic kidney complication (code E10.29) is skeletal muscle GLUT4 in Type 1 diabetes mellitus with other diabetic kidney complication (E10.29: insulin resistance), which Type 1 & Type 2 Diabetes clinicians address while surveilling Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] (4.8% – 5.6% (< 6.5% clinical target) (E10.29)).
Common Symptoms & Clinical Signs
- • Presentation of Type 1 diabetes mellitus with other diabetic kidney complication (E10.29): postprandial afternoon energy in Type 1 diabetes mellitus with other diabetic kidney complication (E10.29: crashes and carbohydrate)
- • Secondary Type 1 diabetes mellitus with other diabetic kidney complication clinical sign: tingling or numbness in Type 1 diabetes mellitus with other diabetic kidney complication (E10.29: in toes and)
- • Symptom flares in Type 1 diabetes mellitus with other diabetic kidney complication correlating with Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (E10.29)
- • Functional diabetes & glucose impact requiring hemoglobin A1c tracking [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] evaluation (E10.29)
Type 1 diabetes mellitus with other diabetic kidney complication Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.29 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] | 4.8% – 5.6% (< 6.5% clinical target) (E10.29) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] | 75 – 95 mg/dL (E10.29) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Type 1 diabetes mellitus with other diabetic kidney complication E10.29] | 3.0 – 7.0 uIU/mL (E10.29) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Type 1 diabetes mellitus with other diabetic kidney complication
Treatment selection for Type 1 diabetes mellitus with other diabetic kidney complication depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Type 1 diabetes mellitus with other diabetic kidney complication)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
Type 1 diabetes mellitus with other diabetic kidney complication Patient Community & “People Like Me” Threads
Filter Type 1 diabetes mellitus with other diabetic kidney complication community threads and patient logs by age, biological sex, dosage, and treatment duration.